CN111362854B - Preparation method of ralotinib intermediate - Google Patents
Preparation method of ralotinib intermediate Download PDFInfo
- Publication number
- CN111362854B CN111362854B CN202010365061.3A CN202010365061A CN111362854B CN 111362854 B CN111362854 B CN 111362854B CN 202010365061 A CN202010365061 A CN 202010365061A CN 111362854 B CN111362854 B CN 111362854B
- Authority
- CN
- China
- Prior art keywords
- difluorophenyl
- butan
- compound
- reaction
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- RMPUOAWHTLSKRE-UHFFFAOYSA-N 4-amino-1-(2,5-difluorophenyl)butan-1-one hydrochloride Chemical compound Cl.NCCCC(=O)C1=C(C=CC(=C1)F)F RMPUOAWHTLSKRE-UHFFFAOYSA-N 0.000 claims abstract description 24
- QIZHVCUPPAMGIW-UHFFFAOYSA-N 5-(2,5-difluorophenyl)-3,4-dihydro-2h-pyrrole Chemical compound FC1=CC=C(F)C(C=2CCCN=2)=C1 QIZHVCUPPAMGIW-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 20
- MCKOYDSNCWNCHG-UHFFFAOYSA-N 4-chloro-1-(2,5-difluorophenyl)butan-1-one Chemical compound FC1=CC=C(F)C(C(=O)CCCCl)=C1 MCKOYDSNCWNCHG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 235000009518 sodium iodide Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229950003970 larotrectinib Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 2
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000003800 Staudinger reaction Methods 0.000 description 2
- 102000005937 Tropomyosin Human genes 0.000 description 2
- 108010030743 Tropomyosin Proteins 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- -1 2, 5-difluorophenyl Chemical group 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 1
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 1
- 101150117329 NTRK3 gene Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 201000010878 atypical lipomatous tumor Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- GJJYYMXBCYYXPQ-UHFFFAOYSA-N tert-butyl 2-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1=O GJJYYMXBCYYXPQ-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 208000022752 well-differentiated liposarcoma Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention discloses a preparation method of a ralotinib intermediate, belonging to the field of drug synthesis, wherein 4-chloro-1- (2, 5-difluorophenyl) butan-1-one (I) is used as a raw material to obtain 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II) through a Delbin reaction, and intramolecular cyclization is performed under an alkaline condition to obtain 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III). The method has mild reaction conditions and simple operation, and is suitable for industrial production.
Description
Technical Field
The invention belongs to the field of drug synthesis, and relates to a synthesis method of an antitumor drug Lalotinib intermediate 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III).
Background
Larotrectinib (LOXO-101) is sold as Vitrakvi, and Chinese translation name is: erlotinib or erlotinib, which is an ATP-competitive, orally selective inhibitor, has a nanomolar 50% inhibitory concentration for three subtypes (TRKA, B and C) of tropomyosin-associated kinase (TRK) family of receptors. 11/27 of 2018, FDA accelerated approval for the co-developed pan-cancer-targeted drug vitrakvi (larotretinib) by Bayer and Loxo Oncology for marketing in adult and pediatric patients with locally advanced or metastatic solid tumors carrying NTRK gene fusion.
The action mechanism is as follows: is a Tropomyosin Receptor Kinase (TRK) inhibitor, can highly specifically inhibit three proteins of TRKA, TRKB and TRKC, and has an effect on tumor patients with TRK fusion variation.
Dosage form and specification: capsules, 25 and 100 mg.
Adverse reactions: fatigue, nausea, dizziness, vomiting, elevated AST, cough, elevated ALT, constipation and diarrhea.
Ralotinib formula: c21H22F2N6O2Molecular weight: 428.4, CAS: 1223403-58-4, chemical name: (3S) -N- [5- [ (2R) -2- (2, 5-difluorophenyl) -1-pyrrolidineBase of]Pyrazolo [1,5-A]Pyrimidin-3-yl]-3-hydroxy-1-pyrrolidinecarboxamide, having the following chemical formula:
wherein 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III) is an important intermediate for synthesizing the ralotinib, and the chemical structural formula is shown as follows:
patent WO2009140128A2 relates to a synthesis method of 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III), and a specific synthetic route is shown as follows:
the process is a simple and feasible route, but the reaction of the first step needs to be carried out at ultralow temperature of-78 ℃, the reaction conditions are harsh, and the price of the N-Boc-2-pyrrolidone is high, so that the route has high production cost and large industrial implementation difficulty.
Chinese patent CN108794370A reports a synthesis process of obtaining 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III) from 4-chloro-1- (2, 5-difluorophenyl) butan-1-one (I) through an azidation reaction and a staudinger reaction, and the specific synthetic route is as follows:
the method is a brand new synthesis route, but virulent sodium azide is used in the azidation reaction, and meanwhile, the sodium azide is explosive, triphenylphosphine is used in the Staudinger reaction, and a byproduct triphenylphosphine oxide is difficult to remove, so that great difficulty is caused in the purification of a product.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a synthetic method of a synthetic ralotinib intermediate 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III).
The invention takes 4-chloro-1- (2, 5-difluorophenyl) butan-1-one (I) as a raw material to obtain 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II) through a Delbin reaction, and the 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III) is obtained through intramolecular cyclization under an alkaline condition, wherein the specific synthetic route is as follows:
s1: adding the compound I, urotropine and a catalyst into a three-necked flask, adding a solvent, reacting for 4 hours at 35-55 ℃, cooling to room temperature of 20-25 ℃ after TLC (thin layer chromatography) controlled reaction is finished, generating a large amount of solid, dropwise adding concentrated hydrochloric acid, continuing stirring for reacting for 2-3 hours after the dropwise adding is finished, clarifying the system, stirring overnight, precipitating a large amount of solid, filtering, and drying to obtain a white solid, namely 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II).
S2: adding 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II) into a three-necked bottle, adding a mixed solvent, adding alkali in batches under the stirring state, raising the temperature to a certain temperature for reacting for 3-4 hours, controlling the reaction in TLC, concentrating the solvent, adding ethyl acetate and water, layering, drying, and concentrating an organic phase to obtain a colorless or pale yellow oily substance, namely 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III).
In step S1, the solvent is one or more of methanol, ethanol, isopropanol, and tert-butanol, preferably the solvent is ethanol; the solvent amount is 3-5 times, preferably 4 times of the mass of the compound I; the catalyst is one of potassium iodide and sodium iodide, and the dosage of the catalyst is 5-10% of the mass of the compound I; the molar ratio of the compound I to the urotropine is 1:1.0-1.3, and the preferable molar ratio is 1: 1.2.
In step S2, the alkali is one or more of potassium carbonate, sodium hydroxide, potassium hydroxide, and lithium hydroxide, preferably potassium carbonate; the molar ratio of the compound (II) to the base is 1: 2-2.5; the mixed solvent is a mixture of water and an organic solvent, wherein the volume ratio of the water to the organic solvent is 1:4, the organic solvent is one of methanol, ethanol, tetrahydrofuran, 1, 4-dioxane and acetonitrile, and the mixed solvent is preferably tetrahydrofuran/water; the reaction temperature is 50-60 ℃.
The invention has the beneficial effects that:
the method comprises the steps of taking 4-chloro-1- (2, 5-difluorophenyl) butan-1-one (I) as a raw material, carrying out a Delbin reaction to obtain 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II), and carrying out intramolecular cyclization under an alkaline condition to obtain 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III). The invention discloses a synthesis method of a ralotinib intermediate, which has the advantages of mild reaction conditions, simplicity in operation, high safety, reduction in production cost and suitability for industrial production.
Detailed Description
Example 1:
preparation of 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II):
adding 50g of 4-chloro-1- (2, 5-difluorophenyl) butan-1-one (1eq) (purchased from Shanghai Haohnhong biomedical science and technology Co., Ltd.), 35g of urotropine (1.1eq), 5g of potassium iodide (10%), adding 300mL of ethanol, reacting at 50 ℃ for 4 hours, after TLC (thin layer chromatography) is finished, cooling to room temperature of 20-25 ℃, generating a large amount of solid, slowly adding 95mL of concentrated hydrochloric acid (5eq, 12M), after finishing adding, continuously stirring and reacting for 2-3 hours, the system becomes clear, is stirred overnight, a large amount of solid is separated out, filtered and dried to obtain 50g of white solid, i.e. 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II), was directly put into the next reaction without further purification.
Preparation of 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III):
50g (1eq) of 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II) is added into a 500mL three-necked flask, 200mL of a mixed solvent of tetrahydrofuran/water (volume ratio 4:1) is added, 32g (2.5eq) of potassium carbonate is added in portions under stirring, the temperature is raised to 55 ℃, the reaction is carried out for 3-4 hours, the TLC is used for controlling the reaction to be finished, the solvent is concentrated, ethyl acetate and water are added, the layers are separated, dried and the organic phase is concentrated to obtain 38g of colorless or light yellow oily matter, namely 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III), and the total yield of the two steps is 91%.
Example 2:
preparation of 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II):
adding 200g of 4-chloro-1- (2, 5-difluorophenyl) butan-1-one (1eq) (purchased from Shanghai Haohnhong biomedical science and technology Co., Ltd.), 128g of urotropine (1eq) and 10g of potassium iodide (5%), adding 1.2L of ethanol, reacting at 50 ℃ for 4h, after TLC is performed, cooling to room temperature of 25 ℃ and a large amount of solid is generated, slowly adding 380mL (5eq) of concentrated hydrochloric acid (12M), stirring for 2h after the dropwise addition is completed, clarifying the system, stirring overnight, precipitating a large amount of solid, filtering, drying to obtain 190g of white solid, namely 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II), and directly putting the mixture into the next reaction without further purification.
Preparation of 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III):
190g (1eq) of 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II) is added into a 2L three-necked flask, 800mL of a mixed solvent of tetrahydrofuran/water (volume ratio 4:1) is added, 97g (2eq) of potassium carbonate is added in portions under stirring, the temperature is raised to 60 ℃, the reaction is carried out for 4 hours, the TLC is controlled to be finished, the solvent is concentrated, ethyl acetate and water are added, layers are separated, the organic phase is dried and concentrated, 147g of colorless or pale yellow oily matter is obtained, namely 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III), and the total yield of the two steps is 88%.
Example 3:
preparation of 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II):
50g of 4-chloro-1- (2, 5-difluorophenyl) butan-1-one (1eq) (available from Haohnhong, Shanghai, Bio-medicine technology Co., Ltd.) and 35g of urotropin (1.1eq) were added to a 500mL three-necked flask, without catalyst, 300mL of ethanol was added, the reaction was carried out at 50 ℃ for 10 hours, and the unreacted reaction was controlled by TLC.
Preparation of 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III):
adding 50g (1eq) of 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II) into a 500mL three-necked bottle, adding 200mL of a mixed solvent of tetrahydrofuran and water (volume ratio is 1:1), adding 19.2g (1.5eq) of potassium carbonate in batches under stirring, reacting for 4 hours at room temperature of 25 ℃, controlling the residual 55% of raw materials in a liquid phase, prolonging the reaction time to 10 hours, controlling the residual 50% of raw materials in the liquid phase, and continuing to prolong the time without change.
Although the present invention has been described with reference to the specific embodiments, it should be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention.
Claims (1)
1. A preparation method of a ralotinib intermediate 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III) comprises the following steps:
s1, reacting 4-chloro-1- (2, 5-difluorophenyl) butan-1-one (I) under the action of a catalyst to obtain 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II), wherein the solvent in the step S1 is one or more of methanol, ethanol, isopropanol and tert-butanol, the amount of the solvent is 3-5 times of the mass of the compound I, and the catalyst is one of potassium iodide and sodium iodide, and the using amount of the catalyst is 5% -10% of the mass of the compound I;
s2, carrying out intramolecular ring closure reaction on 4-amino-1- (2, 5-difluorophenyl) butan-1-one hydrochloride (II) to obtain 5- (2, 5-difluorophenyl) -3, 4-dihydro-2H-pyrrole (III); the alkali adopted in the step S2 is one or more of potassium carbonate, sodium hydroxide, potassium hydroxide and lithium hydroxide, the molar ratio of the compound (II) to the alkali is 1:2-2.5, the mixed solvent is a mixture of water and an organic solvent, and the volume ratio of the water to the organic solvent is 1: 4;
the compound (II) in the step S1 is obtained by carrying out a Delbin reaction on the compound (I) and urotropine;
the mixed solvent in the step S2 is tetrahydrofuran/water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010365061.3A CN111362854B (en) | 2020-04-30 | 2020-04-30 | Preparation method of ralotinib intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010365061.3A CN111362854B (en) | 2020-04-30 | 2020-04-30 | Preparation method of ralotinib intermediate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111362854A CN111362854A (en) | 2020-07-03 |
| CN111362854B true CN111362854B (en) | 2021-04-27 |
Family
ID=71203675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010365061.3A Active CN111362854B (en) | 2020-04-30 | 2020-04-30 | Preparation method of ralotinib intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111362854B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) * | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| CN109310694A (en) * | 2016-04-04 | 2019-02-05 | 洛克索肿瘤学股份有限公司 | Methods of treating pediatric cancers |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010132437A1 (en) * | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
-
2020
- 2020-04-30 CN CN202010365061.3A patent/CN111362854B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109310694A (en) * | 2016-04-04 | 2019-02-05 | 洛克索肿瘤学股份有限公司 | Methods of treating pediatric cancers |
| WO2018165520A1 (en) * | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
Non-Patent Citations (1)
| Title |
|---|
| Cellular Localisation of Antitumoral 6-Alkyl Thymoquinones Revealed by an Alkyne–Azide Click Reaction and the Streptavidin–Biotin System;Katharina Effenberger-Neidnicht et al.;《ChemBioChem》;20110415;第12卷(第8期);第1237-1241页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111362854A (en) | 2020-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2492540C (en) | Modified pictet-spengler reaction and products prepared therefrom | |
| CN115785096B (en) | Method for synthesizing pyrazolone spiro dihydroquinoline or pyrazolone spiro indoline compound with high selectivity | |
| CN110804059B (en) | Carbamate compound, pharmaceutical composition and application thereof | |
| CN111362854B (en) | Preparation method of ralotinib intermediate | |
| CN111393347B (en) | Synthetic method of ralotinib intermediate | |
| US7423152B2 (en) | Process for the manufacture of intermediates in camptothecin production | |
| CN114163445B (en) | Larotrectinib intermediate and preparation method thereof | |
| CN113200932B (en) | Synthetic method of oxazolidinone | |
| CN109963835A (en) | A kind of preparation method of new toxin and its intermediate | |
| CN106831536A (en) | A kind of preparation method of gliclazide green synthesis process | |
| CN109879800B (en) | Preparation process of bepotastine drug intermediate | |
| CN109761956B (en) | Method for synthesizing cyclooctatriene indole derivatives under catalysis of manganese | |
| CN113214101B (en) | Synthesis method of L-tert-leucine and L-cyclohexylalanine | |
| CN116375653B (en) | A method for synthesizing chiral tetrahydroquinazoline derivatives with high enantioselectivity | |
| EP3904340A1 (en) | Synthesis method for halofuginone and intermediate thereof | |
| CN115160234B (en) | Aryl acetate-containing 1,4, 5-trisubstituted imidazole compound, preparation method and application | |
| CN108947900A (en) | The method of carbon arylation tandem reaction synthesizing heterocyclic compound of the photoinduction without metal catalytic | |
| Schulte-Wülwer et al. | Copper (I)-Catalyzed IntramolecularAddition of N-Chloroamides to Double Bonds; an Efficient Synthesis of Lactams from Unsaturated Amides | |
| JP2009096744A (en) | Mannich reaction using cyclic amino ether | |
| CN107935881B (en) | Preparation method of N- [ (2, 4-difluorophenyl) methyl ] -4-methoxy-3-oxobutanamide | |
| Nutaitis et al. | Preparation of benzo [c][2, 7] naphthyridines | |
| CN118666845A (en) | Method for preparing indole[2,3-a]carbazole derivatives using indole as raw material | |
| CN119798327A (en) | A novel chiral nitrogen phosphine ligand compound with quinoline imidazole skeleton and its synthesis method and application | |
| CN117126143A (en) | Method for synthesizing (tetrahydrofuran-2-yl) heteroaromatic compound | |
| CN115181051A (en) | Preparation method of sulfoxide compound containing indole skeleton |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |